The framing is the first problem
"Boosting immunity" is a phrase that sells well and describes nothing.
The immune system is not a dial running from low to high. It is a set of processes that have to be correctly targeted and correctly restrained. Autoimmune disease is the immune system working extremely hard, at the wrong target. Allergy is the same. Chronic inflammation is not a shortage of immune activity.
A compound that produced indiscriminately more immune activity would be dangerous rather than useful. So a claim to boost immunity, taken literally, is a claim nobody should want.
That is worth establishing before looking at the compounds, because it explains why the ones with the most serious research behind them are not sold as boosters at all.
The compounds, and how they differ
Thymosin alpha-1 is the most substantial of the group. It has genuine clinical use in a number of countries outside the United States, mostly as an adjunct in defined conditions. That puts it in a different category from compounds with only preclinical work. It is not approved in the United States, and its use elsewhere is for specific indications, not general enhancement in healthy people.
LL-37 is a human antimicrobial peptide — part of the innate immune system, made by the body as a direct defence against microbes. It is studied for that antimicrobial activity and for wound healing.
It is also studied in the other direction: LL-37 is implicated in some inflammatory skin conditions. A molecule the body makes is not automatically a molecule it is good to add more of, and this one is a clear example.
KPV points the opposite way from the listing it appears on. It is the final three amino acids of alpha-MSH, studied for anti-inflammatory activity — damping signalling rather than raising it. It appears on immunity lists because it relates to the immune system, which is not the same thing.
Thymalin comes from the same Russian research tradition as epitalon, with the same concentration of evidence in the originating institution.
The pattern
The compounds with the most serious evidence in this area — thymosin alpha-1, the body's own cathelicidin — are studied for specific, targeted effects in defined conditions. The general "immune support" claim attaches most readily to the compounds with the least behind them.
That is not a coincidence, and it is the most useful thing to notice on this page.
What each entry says
- Thymosin alpha-1 — a licensed medicine elsewhere, never submitted here
- KPV — three amino acids from a hormone you already have
- What are peptides — the starting point
One immune-signalling peptide sits outside this hub's usual shape: VIP has more human trial literature than anything else in this library and no approved product at all, because most of that research studies the body's own peptide rather than administering one. LL-37 is the same shape again and more extreme: 1,827 human-tagged papers, twenty registry entries, and not one commercial sponsor behind any of them.
Last checked
2026-09-07.